An Analytical Approach to Assess the Predictive Value of Biomarkers in Phase II Decision Making

By Nikolakopoulos Stavros   van der Wal Willem M.   Roes Kit C. B.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 1106-1123

Taylor & Francis Ltd

Access to resources Recommend Favorite

Antineoplastics: reaching phase III RCTs linked to eventual success

By  

Inpharma, Vol. 1, Iss. 1636, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

By Satoh Taroh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1511-1518

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II RAF kinase inhibitors in cancer therapy

By Turajlic Samra   Ali Zohra   Yousaf Nadia   Larkin James  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 739-749

Informa Healthcare

Access to resources Recommend Favorite

Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies

By Zohar Sarah   Chevret Sylvie  

Journal of Biopharmaceutical Statistics, Vol. 17, Iss. 6, 2007-11 ,pp. : 1071-1083

Taylor & Francis Ltd

Access to resources Recommend Favorite